Italian study tracks immunotherapy success in Real-World lung cancer patients
NCT ID NCT06487156
First seen Jan 29, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This study observes 404 adults in Italy with advanced non-small cell lung cancer who are receiving a combination of two immunotherapy drugs (nivolumab and ipilimumab) as their first treatment. The goal is to collect real-world data on how well the treatment works and its safety, rather than testing a new therapy. Participants are not given any experimental treatment; their standard care is simply tracked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Naples, 80131, Italy
Conditions
Explore the condition pages connected to this study.